サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540918

泌尿生殖器用医薬品市場レポート：適応症別、製品別、地域別、2024～2032年

Genitourinary Drugs Market Report by Indication, Product, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
泌尿生殖器用医薬品市場レポート：適応症別、製品別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の泌尿生殖器用医薬品市場規模は2023年に332億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに396億米ドルに達し、2024～2032年の間に1.9％の成長率（CAGR）を示すと予測しています。

泌尿生殖器系には、腎臓、尿管、膀胱、尿道、生殖器などが含まれ、生殖や体内の老廃物の排出に重要な役割を果たしています。その機能は、先天異常、異所性損傷、がん、外傷、感染症、水腎症、炎症などの理由で阻害されることがあります。このような疾病に罹患する患者数が増加しているため、泌尿生殖器治療の需要は世界中で増加しています。泌尿生殖器治療は、生殖器官、排泄系、尿路系疾患の治療に役立ちます。また、膀胱けいれんや勃起不全の治療、早産予防のための子宮収縮抑制にも使用されています。

泌尿生殖器用医薬品市場動向：

泌尿生殖器の障害リスクの増加は、市場の成長に影響を与える主要な要因の一つです。また、泌尿生殖器治療は慢性腎不全や尿路感染症を患う小児患者の治療に有効であるため、世界中で売上が増加しています。これとは別に、市場をリードする企業は、従来の化学療法剤やホルモン療法剤に耐性を獲得した慢性前立腺がん患者の治療に役立つ薬剤を導入するため、製剤化技術の進歩に注力しています。さらに、いくつかの多国籍企業（MNC）は、次世代治療を上市し、市場での地位を強化するために、バイオ医薬品のリーダーと協力しています。これは、後期臨床試験段階にあるパイプライン医薬品の数が大幅に増加していることと相まって、市場の成長に寄与しています。このほか、研究開発（R&D）プロジェクトに対する資金提供の増加や、各国の政府機関や非政府機関が後援する医療インフラの改善も、今後数年間の泌尿生殖器治療の需要を押し上げると予想されます。

本レポートで扱う主要質問

  • 世界の泌尿生殖器用医薬品市場の市場規模は？
  • 2024～2032年における世界の泌尿生殖器用医薬品市場の予想成長率は？
  • 世界の泌尿生殖器用医薬品市場を牽引する主要因は何か？
  • 世界の泌尿生殖器用医薬品市場に対するCOVID-19の影響は？
  • 世界の泌尿生殖器用医薬品市場の適応症別内訳は？
  • 世界の泌尿生殖器用医薬品市場の製品別内訳は？
  • 世界の泌尿生殖器用医薬品市場における主要地域は？
  • 世界の泌尿生殖器用医薬品市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の泌尿生殖器用医薬品市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：適応症別

  • 前立腺がん
  • 卵巣がん
  • 膀胱がん
  • 子宮頸がん
  • 腎臓がん
  • 勃起不全
  • 尿路感染症
  • 尿失禁と過活動膀胱
  • 性感染症
  • 間質性膀胱炎
  • 血尿
  • 前立腺肥大症

第7章 市場内訳：製品別

  • 泌尿器科
  • ホルモン療法
  • 婦人科
  • 抗感染薬
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Allergan plc（AbbVie Inc.）
    • Antares Pharma Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Genentech Inc.（Roche Holding AG）
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Genitourinary Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Genitourinary Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Genitourinary Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Genitourinary Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Genitourinary Drugs Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Genitourinary Drugs Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Genitourinary Drugs (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Genitourinary Drugs (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Genitourinary Drugs (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Genitourinary Drugs (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Genitourinary Drugs (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Genitourinary Drugs (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Genitourinary Drugs (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Genitourinary Drugs (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Genitourinary Drugs (Renal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Genitourinary Drugs (Renal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Genitourinary Drugs (Erectile Dysfunction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Genitourinary Drugs (Erectile Dysfunction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Genitourinary Drugs (Urinary Tract Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Genitourinary Drugs (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Genitourinary Drugs (Interstitial Cystitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Genitourinary Drugs (Interstitial Cystitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Genitourinary Drugs (Hematuria) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Genitourinary Drugs (Hematuria) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Genitourinary Drugs (Urological) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Genitourinary Drugs (Urological) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Genitourinary Drugs (Hormonal Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Genitourinary Drugs (Hormonal Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Genitourinary Drugs (Gynecological) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Genitourinary Drugs (Gynecological) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Genitourinary Drugs (Anti-infectives) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Genitourinary Drugs (Anti-infectives) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Genitourinary Drugs (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Genitourinary Drugs (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia-Pacific: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia-Pacific: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Genitourinary Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Genitourinary Drugs Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Genitourinary Drugs Industry: SWOT Analysis
  • Figure 91: Global: Genitourinary Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Genitourinary Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Genitourinary Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Genitourinary Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Genitourinary Drugs Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Genitourinary Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Genitourinary Drugs Market: Competitive Structure
  • Table 6: Global: Genitourinary Drugs Market: Key Players
目次
Product Code: SR112024A4727

The global genitourinary drugs market size reached US$ 33.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.6 Billion by 2032, exhibiting a growth rate (CAGR) of 1.9% during 2024-2032.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:

The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication and product.

Breakup by Indication:

Prostate Cancer

Ovarian Cancer

Bladder Cancer

Cervical Cancer

Renal Cancer

Erectile Dysfunction

Urinary Tract Infections

Urinary Incontinence and Overactive Bladder

Sexually Transmitted Diseases

Interstitial Cystitis

Hematuria

Benign Prostatic Hyperplasia

Breakup by Product:

Urological

Hormonal Therapy

Gynecological

Anti-infectives

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1. How big is the global genitourinary drugs market?
  • 2. What is the expected growth rate of the global genitourinary drugs market during 2024-2032?
  • 3. What are the key factors driving the global genitourinary drugs market?
  • 4. What has been the impact of COVID-19 on the global genitourinary drugs market?
  • 5. What is the breakup of the global genitourinary drugs market based on the indication?
  • 6. What is the breakup of the global genitourinary drugs market based on the product?
  • 7. What are the key regions in the global genitourinary drugs market?
  • 8. Who are the key players/companies in the global genitourinary drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Genitourinary Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Prostate Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bladder Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cervical Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Renal Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Erectile Dysfunction
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Urinary Tract Infections
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Urinary Incontinence and Overactive Bladder
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Sexually Transmitted Diseases
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast
  • 6.10 Interstitial Cystitis
    • 6.10.1 Market Trends
    • 6.10.2 Market Forecast
  • 6.11 Hematuria
    • 6.11.1 Market Trends
    • 6.11.2 Market Forecast
  • 6.12 Benign Prostatic Hyperplasia
    • 6.12.1 Market Trends
    • 6.12.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Urological
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hormonal Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Gynecological
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-infectives
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 SWOT Analysis
    • 13.3.2 Antares Pharma Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 AstraZeneca plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Bayer AG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Bristol-Myers Squibb Company
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Genentech Inc. (Roche Holding AG)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 GlaxoSmithKline plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Merck & Co. Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Teva Pharmaceutical Industries Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials